CN113365622A - 使用2，3-二氢异吲哚-1-酮化合物的组合疗法及用于治疗具有各种突变的患者的方法 - Google Patents

使用2，3-二氢异吲哚-1-酮化合物的组合疗法及用于治疗具有各种突变的患者的方法 Download PDF

Info

Publication number
CN113365622A
CN113365622A CN201980090539.1A CN201980090539A CN113365622A CN 113365622 A CN113365622 A CN 113365622A CN 201980090539 A CN201980090539 A CN 201980090539A CN 113365622 A CN113365622 A CN 113365622A
Authority
CN
China
Prior art keywords
leukemia
mutation
compound
cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980090539.1A
Other languages
English (en)
Chinese (zh)
Inventor
W·赖斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptose Biosciences Inc
Original Assignee
Aptose Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptose Biosciences Inc filed Critical Aptose Biosciences Inc
Publication of CN113365622A publication Critical patent/CN113365622A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980090539.1A 2018-11-30 2019-12-02 使用2，3-二氢异吲哚-1-酮化合物的组合疗法及用于治疗具有各种突变的患者的方法 Pending CN113365622A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773686P 2018-11-30 2018-11-30
US62/773,686 2018-11-30
PCT/US2019/063993 WO2020113216A1 (en) 2018-11-30 2019-12-02 Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations

Publications (1)

Publication Number Publication Date
CN113365622A true CN113365622A (zh) 2021-09-07

Family

ID=70849819

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090539.1A Pending CN113365622A (zh) 2018-11-30 2019-12-02 使用2，3-二氢异吲哚-1-酮化合物的组合疗法及用于治疗具有各种突变的患者的方法

Country Status (8)

Country Link
US (1) US20200171001A1 (enExample)
EP (1) EP3886840A4 (enExample)
JP (1) JP2022509257A (enExample)
KR (1) KR20210150353A (enExample)
CN (1) CN113365622A (enExample)
AU (1) AU2019387508A1 (enExample)
CA (1) CA3133376A1 (enExample)
WO (1) WO2020113216A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39137A (es) * 2020-04-01 2021-10-29 Fmc Corp Atropisómeros de derivados de piridazinona como herbicidas

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
CN104995184A (zh) * 2012-12-28 2015-10-21 晶体基因技术株式会社 作为btk激酶抑制剂的2,3-二氢异吲哚-1-酮诱导体与含此类的药学组合物
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2018156578A1 (en) * 2017-02-21 2018-08-30 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160312311A1 (en) * 2013-03-12 2016-10-27 Novartis Ag Markers for isocitrate dehydrogenase inhibitors
US20160287592A1 (en) * 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
MA43374A (fr) * 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
MX2018008169A (es) * 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
CN109789127B (zh) * 2016-07-29 2022-03-25 英克特诺治疗公司 吲哚啉酮化合物的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047017A2 (ko) * 2010-10-05 2012-04-12 크리스탈지노믹스(주) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
CN104995184A (zh) * 2012-12-28 2015-10-21 晶体基因技术株式会社 作为btk激酶抑制剂的2,3-二氢异吲哚-1-酮诱导体与含此类的药学组合物
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2018081830A1 (en) * 2016-10-31 2018-05-03 Oregon Health & Science University Combinations of agents to treat hematological malignancies
WO2018156578A1 (en) * 2017-02-21 2018-08-30 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
程井军: "《中国肿瘤临床年鉴 2012》", 中国协和医科大学出版社, pages: 220 - 178 *

Also Published As

Publication number Publication date
EP3886840A4 (en) 2022-08-24
EP3886840A1 (en) 2021-10-06
CA3133376A1 (en) 2020-06-04
JP2022509257A (ja) 2022-01-20
US20200171001A1 (en) 2020-06-04
WO2020113216A1 (en) 2020-06-04
AU2019387508A1 (en) 2021-06-10
KR20210150353A (ko) 2021-12-10

Similar Documents

Publication Publication Date Title
JP7431309B2 (ja) 血液悪性腫瘍患者の治療方法
US20210214373A1 (en) Macrocyclic compounds and uses thereof
CN109970742A (zh) 选择性PI3Kδ抑制剂
KR20230162137A (ko) (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도
WO2017066193A1 (en) Novel inhibitors of protein kinases
Cheng et al. Pharmacological inhibition of NF-κB-inducing kinase (NIK) with small molecules for the treatment of human diseases
US11142533B2 (en) Macrocycles for use in treating disease
WO2013044596A1 (zh) 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
CN103648500B (zh) 双功能酶制钳型分子的方法和用途
CN109641890A (zh) 异柠檬酸脱氢酶(idh)抑制剂
US20200171001A1 (en) Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
US12258315B2 (en) S6K1 protein kinase inhibitors as cancer therapeutics
US11066372B2 (en) Deuterated benzimidazole compound and medical use thereof
US20230406804A1 (en) Protein kinase inhibitors
WO2015009882A2 (en) Cyano derivatives and their uses
HK40014760A (en) Methods for treating patients with hematologic malignancies
CN121202878A (zh) 一种c-Met抑制剂及其制备方法和应用
OA19985A (en) Macrocyclic compounds and uses thereof.
HK1194308B (en) Methods and use of bifunctional enzyme-building clamp-shaped molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210907

WD01 Invention patent application deemed withdrawn after publication